Sigyn Therapeutics (SIGY) EBT (2017 - 2025)
Sigyn Therapeutics (SIGY) posted EBT of -$578503.0 for Q3 2025, up 60.14% sequentially from -$1.5 million in Q2 2025, and up 51.67% YoY from -$381428.5 in Q3 2024.
Sigyn Therapeutics (SIGY) EBT (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported EBT for 9 years, with the latest figure at -$578503.0 in Q3 2025.
- Quarterly EBT rose 51.67% year-over-year to -$578503.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$3.2 million (up 19.34% YoY) and the FY2024 annual result came in at -$3.3 million, up 19.43% from the prior year.
- EBT climbed to -$578503.0 in Q3 2025 per SIGY's latest filing, from -$1.5 million in the prior quarter.
- Over five years, EBT peaked at -$461682.0 in Q1 2021 and troughed at -$1.5 million in Q2 2025.
- A 5-year average of -$848359.9 and a median of -$726509.0 in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2021 and 2024: EBT slumped 171.49% in 2021, then jumped 55.54% in 2024.
- Over 5 years, EBT stood at -$1.2 million in 2021, then jumped by 30.01% to -$858937.0 in 2022, then plunged by 36.92% to -$1.2 million in 2023, then surged by 55.54% to -$522818.0 in 2024, then decreased by 10.65% to -$578503.0 in 2025.
- According to Business Quant data, EBT over the past three periods registered -$578503.0, -$1.5 million, and -$668564.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -578,503.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -578,503.00 |
| Jun 30, 2025 | -1.45 Mn |
| Mar 31, 2025 | -668,564.00 |
| Dec 31, 2024 | -522,818.00 |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -862,383.00 |
| Mar 31, 2024 | -758,088.00 |
| Dec 31, 2023 | -1.18 Mn |
| Sep 30, 2023 | -905,726.00 |
| Jun 30, 2023 | -723,124.00 |
| Mar 31, 2023 | -1.34 Mn |
| Dec 31, 2022 | -858,937.00 |
| Sep 30, 2022 | -726,509.00 |
| Jun 30, 2022 | -666,325.00 |
| Mar 31, 2022 | -678,046.00 |
| Dec 31, 2021 | -1.23 Mn |
| Sep 30, 2021 | -665,904.00 |
| Jun 30, 2021 | -649,861.00 |
| Mar 31, 2021 | -461,682.00 |
| Dec 31, 2020 | -452,022.00 |